The Punjab and Haryana High Court has provided interim relief to Panacea Biotec. The court has stayed any coercive action regarding Goods and Services Tax on corporate guarantees. This applies to guarantees issued before a recent amendment to the CGST Rules. The court is examining the retrospective application of GST.

India’s equity benchmarks slipped on Friday as volumes thinned toward the year-end, with analysts saying that an advance depended on momentum from the quarterly earnings season starting next month. The Nifty 50 index fell 0.25% to 26,077.85, while the BSE Sensex index shed 0.26% to 85,186.61, as of 9:54 a.m. IST. Most Asian markets, including India, were closed on Thursday for the Christmas holiday. Twelve of the 16 major sectors logged losses. Both the Nifty and Sensex hit record highs in November after 14 months, but have remained subdued so far in December, shedding about 0.3% and 0.5%, respectively. “We expect Indian equities to trade in a narrow range in the remaining sessions of 2025 due to a lack of triggers and reduced trading activity due to holidays across several global markets,” said Siddhartha Khemka, head of research of wealth management at Motilal Oswal Financial Services. Financial institutions such as banks and investment firms likely indulged in year-end book squaring, a process to close out or rebalance their positions to tidy up books.

Panacea Biotec has secured a significant deal to supply bivalent oral polio vaccines valued at Rs 127.2 crore to the Central Medical Services Society. This crucial supply, confirmed via a Letter of Acceptance, will be delivered in multiple phases over 90 to 480 days, bolstering India's ongoing polio eradication efforts.

Hyderabad’s AIIMS Bibinagar has emerged as a crucial site for India’s first indigenous dengue vaccine, currently in phase III clinical trials. Led by ICMR and developed in partnership with Panacea Biotec, the single-shot tetravalent vaccine is in its final phase of enrollment.

New Delhi, Aug 1 : The phase III clinical trial for Indias 1st dengue vaccine has enroled 70 per cent participants, said Union Minister of State for Health, Prataprao Jadhav, in the Parliament on Friday. In a written reply to the Lok Sabha, Jadhav shared details on the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll. The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed, Jadhav said. The trial is likely to be completed by October. The trial has been implemented in 20 sites across India. The approximate budget is Rs 1.3 to 1.5 crore per site for the trial, he added. The indigenous tetravalent dengue vaccine, DengiAll, is being developed by Panacea Biotec under a licensing agreement with the National Institutes of Health (NIH). The vaccine targets all four dengue virus subtypes and has shown promising results in earlier clinical trials. As per data from the National Centre for Disease Control (NCDC), a total of 5,73,563 laboratory-confirmed (L form) dengue cases were reported in 2024.